Risk factors

Company faces heavy concentration risk with 68.3 percent of gross written premiums distributed through just four brokers. Reliance on AmFam partnership is critical for legal entities, ratings, and licenses with AmFam owning 14.4 percent. Limited operating history since September 2020 increases reliance on third-party data and models.

BXP operates a real estate portfolio heavily concentrated in six major metropolitan markets facing localized economic risks. The company carries substantial leverage, with $15.7 billion in consolidated debt exposed to refinancing and interest rate pressures. Operations face environmental, climate, cyber, and tenant bankruptcy hazards across office, life sciences, and mixed-use assets.

Automotive market cycles, OEM and dealer concentration, and competitive pressure heavily dominate Cars.com risk disclosures.

Chubb operates globally across 54 countries facing natural and man-made disaster risks that could impact loss reserves and capital. The company faces increasing tax risks including a 15 percent Bermuda income tax and global minimum tax measures. Regulatory, cybersecurity, and evolving privacy laws create significant operational and compliance burdens.

C4 Therapeutics faces ongoing losses, accumulating a deficit of $633.7 million through December 31, 2024.

Codexis faces significant ongoing net losses with an accumulated deficit of $562.8 million as of December 31, 2024. Revenue is heavily concentrated, with customers contributing 10% or more accounting for 51% of total revenue in 2024. The company relies heavily on unproven novel technologies like the ECO Synthesis manufacturing platform for enzymatic nucleic acid synthesis.

CEVA relies heavily on semiconductor IP licensing in China, facing risks from US export controls, Middle East conflict, and high competition.

Commercial real estate and consumer auto loans represent 55 percent of the portfolio, carrying heightened concentration risk. Regional economic health in Virginia and the Mid-Atlantic dictates core banking performance. Strict federal regulation, interest rate volatility, and cybersecurity threats heavily impact operations.

Carlyle’s results depend heavily on investment performance, realizations, fundraising, and carried-interest economics.

Clinical development of drug candidates like CLN-619, CLN-978, and zipalertinib dominates risk exposure. Substantial financial losses, reliance on limited capital, and heavy competition shape prospects. Transitioning off emerging growth company status introduces higher compliance costs.

Chord Energy is heavily exposed to commodity price volatility and geographic concentration in the Williston Basin. Operations face significant risks from regulatory compliance on federal and tribal lands and capital constraints.

Cigna faces intense industry competition and price pressure across health services and pharmacy benefit management operations. Substantial regulatory oversight governs government-sponsored programs, privacy laws, and pharmaceutical manufacturer rebates. IT infrastructure stability and cybersecurity threats are critical operational dependencies for customer data.